首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1544626

兒科疫苗市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Pediatric Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月09日 | 出版商:

Global Market Insights Inc. | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在合作夥伴關係和投資不斷增加的推動下，兒科疫苗市場規模預計 2024 年至 2032 年間複合年成長率將達到 8.9%。

最近，各組織正合作加強研發活動，為兒童生產更有效、更容易取得的疫苗。這些投資為新疫苗配方和技術鋪平了道路，增強了對一系列疾病的保護。這種對投資和合作的堅定承諾確保疫苗與健康挑戰同步發展，最終促進全球兒童獲得更好的健康結果。例如，2023 年 9 月，葛蘭素史克 (GSK) 與救助兒童會 (Save the Children) 的合作關係又延長了五年。葛蘭素史克 (GSK) 正在撥款 1500 萬英鎊來提高疫苗接種率，特別關注埃塞俄比亞和奈及利亞的「零劑量」兒童。

兒科疫苗產業根據類型、技術、適應症、最終用途和地區進行細分。

由於人們越來越傾向於針對單一病原體或其特定菌株，因此單價疫苗類型細分市場的市場佔有率預計到 2032 年將大幅成長。單價疫苗透過集中針對單一病毒或細菌來針對兒科族群中的疾病。這些疫苗正在接受嚴格的臨床試驗，以增強其功效和安全性。因此，不斷取得的進步正在對單價疫苗進行微調，使其不僅更有效，而且更容易管理，從而增強兒科護理中的疾病預防。

就最終用途而言，由於越來越重視兒童及時有效的免疫接種，私部門的兒科疫苗市場價值預計將在 2024 年至 2032 年期間產生可觀的收入。醫療機構正在加強疫苗接種服務，以確保年輕患者獲得徹底的免疫接種。私人診所正在實現產品多元化，提供廣泛的兒科疫苗，以滿足各種健康需求和預防疾病。此外，疫苗技術和給藥方法的創新正在提高私人診所中兒科疫苗的有效性和便利性。

在全球健康計劃的帶動下，到 2032 年，歐洲兒科疫苗產業規模可能會顯著成長。一些國家正在聯手實施旨在透過全面的疫苗接種策略來促進兒童健康的計畫。隨著全球衛生組織加強擴大疫苗覆蓋率，歐洲醫療保健提供者正在透過加強其私人疫苗接種服務來應對。這項持續的合作旨在提高整個歐洲兒童的疫苗接種率並改善健康。

產業生態系統分析
產業影響力
- 成長動力
  - 兒童慢性病和傳染病的發生率上升
  - 出生率增加
  - 疫苗開發的研究和開發活動不斷增加
  - 政府措施和資金不斷增加
- 產業陷阱與挑戰
  - 已開發國家疫苗核准監管嚴格
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

主要趨勢
單價疫苗
多價疫苗

第 6 章：市場估計與預測：按技術分類，2021 - 2032 年

主要趨勢
減毒活疫苗
去活化疫苗
類毒素疫苗
結合疫苗
其他技術

第 7 章：市場估計與預測：按指標分類，2021 - 2032 年

主要趨勢
流感
人類乳突病毒
麻疹、腮腺炎和德國麻疹
小兒麻痺
肺炎球菌疾病
白喉、百日咳和破傷風
其他適應症

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
民眾
私人的

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Astellas Pharma, Inc.
AstraZeneca Plc
CSL Limited
Daiichi Sankyo Company Limited
Emergent BioSolutions, Inc,
GlaxoSmithKline Plc
Grifol SA
Meissa Vaccines, Inc.
Merck and Co. Inc.
Panacea Biotec
Pfizer, Inc.
Sanofi SA
Serum Institute of India
Takeda Pharmaceutical Industries Limited

簡介目錄

Product Code: 10161

Pediatric Vaccines Market size is expected to record an 8.9% CAGR between 2024 and 2032, driven by increasing partnerships and investments.

Of late, organizations are collaborating to bolster R and D activities to produce more effective and accessible vaccines for children. These investments are paving the way for new vaccine formulations and technologies, enhancing protection against a range of diseases. This steadfast commitment to investment and collaboration ensures that vaccines evolve in tandem with health challenges for ultimately promoting better health outcomes for children globally. For example, in September 2023, GSK and Save the Children extended their partnership for another five years. GSK is channeling £15 million to elevate vaccination rates, with a particular focus on 'zero dose' children in Ethiopia and Nigeria.

The pediatric vaccines industry is segmented based on type, technology, indication, end-use, and region.

The market share from the monovalent vaccines type segment is expected to witness substantial growth through 2032, due to the rising preference for targeting individual pathogens or their specific strains. Monovalent vaccines focus on diseases within pediatric populations by concentrating on a singular virus or bacterium. These vaccines are undergoing stringent clinical trials to bolster their efficacy and safety. As a result, ongoing advancements are fine-tuning monovalent vaccines, making them not only more effective but also easier to administer, thereby amplifying disease prevention in pediatric care.

In terms of end-use, the pediatric vaccines market value from the private segment is slated to generate notable revenue during 2024-2032 driven by the growing emphasis on timely and effective immunizations for children. Healthcare facilities are ramping up their vaccination services to ensure thorough immunization for their young patients. Private clinics are diversifying their offerings, providing a broad spectrum of pediatric vaccines to meet various health needs and prevent diseases. Furthermore, innovations in vaccine technology and delivery methods are boosting the effectiveness and ease of pediatric vaccines in private practices.

Europe pediatric vaccines industry size is likely to record a significant growth rate through 2032 led by global health initiatives. Several countries are joining forces on programs aimed at bolstering child health through comprehensive vaccination strategies. With global health organizations intensifying their efforts to amplify vaccine coverage, European healthcare providers are responding by enhancing their private vaccination services. This ongoing collaboration is set to elevate vaccination rates and improve health outcomes for children throughout Europe.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of chronic and infectious disease in children
  - 3.2.1.2 Increasing birth rate
  - 3.2.1.3 Growing research and development activities for vaccine development
  - 3.2.1.4 Rising government initiatives and funding
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Stringent regulations for the approval of vaccines in developed nations
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

5.1 Key trends
5.2 Monovalent vaccines
5.3 Multivalent vaccines

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Million)

6.1 Key trends
6.2 Live attenuated vaccines
6.3 Inactivated vaccines
6.4 Toxoid vaccines
6.5 Conjugate vaccines
6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)

7.1 Key trends
7.2 Influenza
7.3 Human papilloma virus
7.4 Measles, mumps, and rubella
7.5 Polio
7.6 Pneumococcal disease
7.7 Diphtheria, pertussis, and tetanus
7.8 Other indications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)

8.1 Key trends
8.2 Public
8.3 Private

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa